Tandem Diabetes Care (NASDAQ:TNDM) Third Quarter 2024 Results
Key Financial Results
- Revenue: US$244.0m (up 31% from 3Q 2023).
- Net loss: US$23.3m (loss narrowed by 30% from 3Q 2023).
- US$0.35 loss per share (improved from US$0.51 loss in 3Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Tandem Diabetes Care Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 8.9%. Earnings per share (EPS) also surpassed analyst estimates by 16%.
Looking ahead, revenue is forecast to grow 10% p.a. on average during the next 3 years, compared to a 8.3% growth forecast for the Medical Equipment industry in the US.
Performance of the American Medical Equipment industry.
The company’s shares are up 4.4% from a week ago.
Risk Analysis
You still need to take note of risks, for example – Tandem Diabetes Care has 1 warning sign we think you should be aware of.
Valuation is complex, but we’re here to simplify it.
Discover if Tandem Diabetes Care might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free Analysis
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
